If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the war against the Marcomanni in 167, the town was hard pressed; its fortifications had fallen into disrepair during the long peace. Nevertheless, when in 168 Marcus Aurelius made Aquileia the principal fortress of the empire against the barbarians of the North and East, it rose to the pinnacle of its greatness and soon had a population of 100,000. Septimius Severus visited in 193. In 238, when the town took the side of the Senate against the emperor Maximinus Thrax, the fortifications were hastily restored, and proved of sufficient strength to resist for several months, until Maximinus himself was assassinated.
== Prognosis == Five year survival in those with PAH was only 34%, but this has improved since the early 2000s when disease specific therapy was introduced. In 2010, survival was 86%, 69%, and 61% at 1, 3 and 5 years respectively. Heritable PAH is associated with an earlier disease onset, more severe hemodynamic features, and a reduced response to therapy as compared to idiopathic PAH. In those with scleroderma associated PAH, 3 year survival is 56% as compared to 94% in those with scleroderma without PAH. Those with PAH responding to vasodilators have a better prognosis. PAH is associated with right heart failure and death (with a mortality rate of 13-17%) in pregnant women. It is recommended that women with PAH who may become pregnant use contraception. Estrogen containing contraceptives should be avoided due to the risk of blood clots.
=== Discovery, regulation and marketing === Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis as well as Docefrez by Sun Pharma Global and Zytax by Zydus. Annual sales of Taxotere in 2010 were €2.122 billion (US$3.1 billion). The patent expired in 2010. Docetaxel was developed by Rhône-Poulenc Rorer (now Sanofi-Aventis) following from the discoveries of Pierre Potier at CNRS at Gif-sur-Yvette during his work on improvements to the production of paclitaxel (Taxol) using the local European yew.
Sources: en.wikipedia.org
Plastic (high-density polyethylene) Composite: steel and plastic Carbon steel Stainless steel (304 and 316/316L SS grades) Some IBC engineering models are foldable (collapsible) for space-saving breakdown following use.
Sendai virus is used as a backbone for vaccine development against Mycobacterium tuberculosis that causes tuberculosis, against HIV-1 that causes AIDS and against other viruses, including those that cause severe respiratory infections in children. The latter include human respiratory syncytial virus (HRSV), human metapneumovirus (HMPV) and human parainfluenza viruses (HPIV). The vaccine studies against M. tuberculosis, HMPV, HPIV1 and, HPIV2 are in the pre-clinical stage, against HRSV a phase I clinical trial has been completed. The phase I clinical studies of SeV-based vaccination were also completed for HPIV1. They were done in adults and in 1–6-year-old children. As a result of vaccination against HPIV1, a significant boost in virus-specific neutralizing antibodies was observed. A SeV-based vaccine development against HIV-1 has reached a phase II clinical trial. In Japan intranasal Sendai virus-based SARS-CoV-2 vaccine was created and tested in a mouse model. More recent applications (2024–2025) include non-integrative gene delivery for fertility restoration in mouse models, enhanced transduction in pancreatic cancer, and temperature-sensitive platforms for CRISPR-Cas9 editing in human stem cells and viral genome engineering.
The BacT/ALERT system, which indirectly detects production of CO2 by measuring the decrease in the medium's pH, was approved for use in the US in 1991. Unlike the BACTEC systems available at the time, the BacT/ALERT did not require a needle to be introduced into the bottle for sampling; this reduced the frequency of contamination and made it the first system to provide truly continuous monitoring of blood cultures. This non-invasive measurement method was adopted in 1992 by the BACTEC 9000 series, which used fluorescent indicators to detect pH changes. The Difco ESP, a direct predecessor of the contemporary VersaTREK system which detects gas production by measuring pressure changes, was also first approved in 1992. By 1996, an international study found that 55% of 466 laboratories surveyed were using the BACTEC or BacT/ALERT systems, with other automated systems accounting for 10% of the total.
== Awards and honors == 2003: USC Renaissance Scholar 2003: USC Chemistry Alumni Award for Outstanding Undergraduate Research 2006: Student Travel Award for Australian Peptide Society 2008: Poster Prize, Science at the Interface (University of Chicago) 2010: Collier Award, Gordon Conference, Microbial Toxins and Pathogenicity 2012: Vallee Foundation Travel Award 2013: Damon Runyon-Rachleff Innovation Award 2013: Young Chemical Biologist Award, International Chemical Biology Society 2013: Sontag Distinguished Scientist Award 2014: NSF CAREER Award 2015: Sloan Research Fellowship in Chemistry 2015: Novartis Early Career Award in Organic Chemistry 2016: Amgen Young Investigator Award 2018: Eli Lilly Award in Biological Chemistry 2021: Rao Makineni Lectureship, American Peptide Society Source:
Sources: en.wikipedia.org
=== Function during breastfeeding === Oxytocin has a crucial role in the process of milk ejection. After sucking, the release of oxytocin stimulates the myoepithelial cell contraction in the breast, which forces milk to move from the alveoli, via the milk ducts, and towards the nipple. Oxytocin is secreted quicker than prolactin. It facilitates the flow of pre-existing breast milk for the current feeding, hence helping the infant in obtaining milk easily.
15 January – Train passengers using the South West Main Line are warned to expect major disruptions after a section of the track north of Hook railway station in Hampshire collapsed due to a landslide. 16 January – At London's Southwark Crown Court, former Metropolitan Police Parliamentary and Diplomatic Protection officer David Carrick admits over 40 offences including over 20 rapes. 23 January – Salisbury Crown Court in Wiltshire convicts Lawangeen Abdulrahimzai, an Afghan who committed a double murder in Serbia before moving to the UK as an asylum seeker, by pretending to be a 14-year-old refugee, of a murder he committed in Bournemouth, Dorset, in 2022. 25 January – Lawangeen Abdulrahimzai is sentenced to life imprisonment with a minimum of 29 years for the March 2022 murder of Thomas Roberts.
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350–400 amino acids in length. The lipid modification of all Wnts is palmitoleoylation of a single totally conserved cysteine residue. Palmitoleoylation is necessary because it is required for Wnt to bind to its carrier protein Wntless (WLS) so it can be transported to the plasma membrane for secretion and it allows the Wnt protein to bind its receptor Frizzled Wnt proteins also undergo glycosylation, which attaches a carbohydrate in order to ensure proper secretion. In Wnt signaling, these proteins act as ligands to activate the different Wnt pathways via paracrine and autocrine routes. These proteins are highly conserved across species. They can be found in mice, humans, Xenopus, zebrafish, Drosophila and many others.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.